Passa al contenuto
Merck

Concomitant gain and loss of function pathomechanisms in C9ORF72 amyotrophic lateral sclerosis.

Life science alliance (2021-02-24)
Arun Pal, Benedikt Kretner, Masin Abo-Rady, Hannes Glaβ, Banaja P Dash, Marcel Naumann, Julia Japtok, Nicole Kreiter, Ashutosh Dhingra, Peter Heutink, Tobias M Böckers, René Günther, Jared Sterneckert, Andreas Hermann
ABSTRACT

Intronic hexanucleotide repeat expansions (HREs) in C9ORF72 are the most frequent genetic cause of amyotrophic lateral sclerosis, a devastating, incurable motoneuron (MN) disease. The mechanism by which HREs trigger pathogenesis remains elusive. The discovery of repeat-associated non-ATG (RAN) translation of dipeptide repeat proteins (DPRs) from HREs along with reduced exonic C9ORF72 expression suggests gain of toxic functions (GOFs) through DPRs versus loss of C9ORF72 functions (LOFs). Through multiparametric high-content (HC) live profiling in spinal MNs from induced pluripotent stem cells and comparison to mutant FUS and TDP43, we show that HRE C9ORF72 caused a distinct, later spatiotemporal appearance of mainly proximal axonal organelle motility deficits concomitant to augmented DNA double-strand breaks (DSBs), RNA foci, DPRs, and apoptosis. We show that both GOFs and LOFs were necessary to yield the overall C9ORF72 pathology. Increased RNA foci and DPRs concurred with onset of axon trafficking defects, DSBs, and cell death, although DSB induction itself did not phenocopy C9ORF72 mutants. Interestingly, the majority of LOF-specific DEGs were shared with HRE-mediated GOF DEGs. Finally, C9ORF72 LOF was sufficient-albeit to a smaller extent-to induce premature distal axonal trafficking deficits and increased DSBs.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
Poli-L-ornitina, mol wt 30,000-70,000, 0.01%, sterile-filtered, BioReagent, suitable for cell culture
Sigma-Aldrich
Anticorpo anti fosfo-istone H2A.X (Ser139), colone JBW301, clone JBW301, Upstate®, from mouse
Roche
Laminina, from mouse Engelbreth-Holm-Swarm (EHS) sarcoma
Sigma-Aldrich
Etoposide, synthetic, 95.0-105.0%, powder
Sigma-Aldrich
(S)-(+)-Camptothecin, ≥90% (HPLC), powder
Roche
Ribonuclease H (RNase H), from Escherichia coli H 560 pol A1
Sigma-Aldrich
Topoisomerase II Inhibitor, BNS-22, The Topoisomerase II Inhibitor, BNS-22 controls the biological activity of Topoisomerase. This small molecule/inhibitor is primarily used for Cell Structure applications.